Point72 Asset Management
ANIP icon

Point72 Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Point72 Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-121,211
Closed -$9.57M – 3751
2025
Q4 		$9.57M Sell
121,211
-277,881
-70% -$24.1M 0.01% 1378
2025
Q3 		$36.6M Buy
+399,092
New +$32.5M 0.06% 341
2023
Q3 		– Sell
-776
Closed -$41.8K – 2438
2023
Q2 		$41.8K Buy
776
+291
+60% +$12.9K ﹤0.01% 1641
2023
Q1 		$19.3K Buy
+485
New +$20.5K ﹤0.01% 1972

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Point72 Asset Management's ANIP Position: Q1 2026 in Review

Point72 Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 121,211 shares — an estimated $9.57M sold.

Point72 Asset Management first reported a position in ANIP in Q1 2023 and held it in 4 quarters. The position peaked at $36.6M in Q3 2025. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Point72 Asset Management reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 121,211 ANI Pharmaceuticals shares in Q1 2026, an estimated $9.57M.
  • Point72 Asset Management first reported a position in ANI Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Point72 Asset Management's ANI Pharmaceuticals position peaked at $36.6M in Q3 2025.
  • 281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.